framework contract for the supply of the latest approved protein based COVID-19 vaccines
Awarded
The competition has ended and a winner has been selected.
- Qualification deadline
- Nov 13, 2025Expired
- Award
- Pris 30%
Brief
The European Commission, DG HERA - European Health Emergency Preparedness and Response Authority, has entered into a framework agreement with HIPRA HUMAN HEALTH SL, HIPRA SCIENTIFIC SL, and LABORATORIOS HIPRA SA for the supply of the latest approved protein-based COVID-19 vaccines, up to 4,000,000 doses, for a duration of 24 months. The contractor is required to ensure the vaccine is adapted to relevant variants for the European Union population and ensure availability of adapted vaccines in accordance with expert recommendations, with assessments for adaptation conducted at least yearly. One bid was received for this contract.
Farmasøytisk engroshandel
Result
- HIPRA HUMAN HEALTH SLWinner
- HIPRA SCIENTIFIC SLWinner
- LABORATORIOS HIPRA SAWinner
- 1Number of bids
- Not statedContract value
- Maximum framework agreement valueUp to €0
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
Vennligst se anskaffelsesdokumentene.
Source
No source found in the documents. Check the weight against the tender documents.
Description
Vennligst se anskaffelsesdokumentene.
Source
No source found in the documents. Check the weight against the tender documents.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at European Commission, DG HERA - European Health Emergency Preparedness and Response Authority
From the notice
The subject of this contract is the supply of the latest approved protein based COVID-19 vaccines up to 4,000,000 doses. Throughout the delivery schedule and/or duration of the contract (whichever lasts longer), the contractor shall ensure that the vaccine is adapted to the relevant variants for the European Union population and ensure availability of adapted vaccines in accordance with the most recent Experts recommendations on the need for updating the strain composition of C19 vaccines. The necessity of adapting the vaccine shall be assessed at least yearly, on time, to start timely distribution of updated vaccines for vaccination during second half of the year, unless other timing of updates is considered necessary. The contractor shall also ensure any other relevant changes to the vaccine, as necessary, to address efficacy and safety needs of the product and to enable adequate immunization activities by the participating countries.
Contact
HERA-JOINT-PROCUREMENT-secretariat@ec.europa.eu- Result · Framework agreement · PrequalificationType
- 33600000Main codePharmaceutical products